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Editorial on the Research Topic
Epigenetic Reprogramming and Cancer Development
For many years, scientists focused on the protein products of oncogenes driving cancer by
disrupting non-nuclear events, such as the signal transduction events within cells. For example,
the Ras oncogene encodes a GDP/GTP-binding guanine triphosphatase that dysregulates the signal
transduction for cell growth and differentiation and the p210BCR/ABL protein encoded by BCR-ABL
fusion gene in chronic myeloid leukemia (CML) contributes to transformation as a constitutively
active tyrosine kinase in the cytoplasm. Events that disrupt the signals cells receive from their
environment are clearly important because normal cells are “socially” responsive, whereas we
view the behavior of cancer cells as anarchic. Conrad H. Waddington’s epigenetic landscape
brought to attention the importance of a cell’s “social” environment and that the signals received
regulate gene expression and cell status. However, and at the time, epigenetics was in its infancy,
lacking an appreciation of DNA and histonemodifications that control gene expression. Nowadays,
epigenetic controls on gene outputs, nurtured by environmental signals, are crucial to normal cell
development and have an accepted role in the initiation and progression of cancer.
For many years, scientists have studied hematopoietic stem cells (HSC) to delineate the
behavior of normal tissue-specific stem cells. They assigned each of the different leukemias to their
cell-of-origin by means of a precise map of the stepwise progression of HSCs, via intermediate
progenitor cells (HPCs), toward an end cell type. However, recent findings have radically changed
our understanding of HSCs development. Brown and Ceredig argue that commitment/affiliation
to a single cell lineage can occur within HSCs, but these cells and HPCs can still divert to another
pathway. Recent findings have also brought to attention the importance of environmental signals
to decision-making by HSCs. Since their discovery, we have viewed hematopoietic cytokines as
supportive to cell survival and proliferation but we now know that some also instruct the choice of
cell lineage by HSCs and HPCs.
Most leukemias and other cancers arise from a tissue-specific stem cell and, in contrast to
the versatility of HSCs, leukemia and cancer cells often belonging to one cell lineage. One
explanation is that the cell-of-origin is already lineage committed, for example, childhood acute
leukemia (ALL) cells express B-cell or T-cell markers indicating a B-cell or T-cell progenitor
origin, respectively. However, recent evidence favors a fetal liver HSC as the cell-of-origin
and Raboso-Gallego et al. put forward a different explanation for the lineage affiliation of
leukemia cells seen in childhood ALL. Their view is that an oncogene “hit-and-run” event
in a HSC forces cells down a lineage by priming the epigenome of the leukemia-initiating
cell (LIC). Consequentially, the leukemia stem cell arising from the LIC and partially
differentiated ALL cells have the same fixed identity. NOTCH1 gain-of function mutations
lead to aberrant signaling in T-cell ALL and the research article by Tottone et al. shows that
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epigenetic events, namely active histone H3 lysine 27 (H3K27)
marks, sustain the expression of aberrant Notch3. Importantly,
pharmacological inhibition of H3K27 modifiers (JMJD3 and
p300) reduced the expression ofNOTCH3, NOTCH1, and of their
target genes. As outlined by Yang and Green, there is also a strong
epigenetic component to the identity of B cell lymphomas. The B
cell lymphoma (BCL6) gene encodes a transcription factor that
plays a role in B cell germinal centers and complex interplay
between BCL6 function and epigenetic events are of critical
importance to the development of B cell lymphoma. For example,
BCL6 cooperates with the EZH2 gene that encodes a H3K27
methyltransferase and binds directly to histone demethylase
LSD1 that demethylates H3K4me1/2. The findings presented
support targeting BCL6 and epigenetic cross talk to treat B
cell lymphoma.
As to malfunctioning of the immune system, the
immunodeficiencies are a large group of different diseases
that increase the risk of cancer in addition to having significant
morbidity and, in some cases, mortality. Martínez-Cano et al.
propose that epigenetic priming is the “third axis” to the
genetic and environmental causes of immunodeficiencies,
including the possibility of a triggered epigenetic mechanism.
In secondary immunodeficiencies, it is increasingly becoming
clear that environmental agents play a key role in triggering the
epigenetic alterations.
Epigenetic programming in cancer has important
implications to finding new approaches to treating, including
perhaps curing, cancer. The use of tyrosine kinases inhibitors to
overcome the activity of BCR-ABL protein in CML has improved
treatment but not cured patients. Bugler et al. review the potential
of emerging epigenetic therapies to eradicate cancer stem cells
and residual disease and, in combination with current therapies,
provide a cure. Epigenetic modifiers, such as SIRT1, HDAC,
and EZH2 inhibitors, have been very effective in mouse models
of cancer and there are in clinical trials in some cancers. The
good safety profiles of modifiers in healthy individuals support
trails in CML. The research report by Rivas et al. examines
hepatoblastoma that is characterized by hypermethylation at
particular CpG islands. As to a role for epigenetic dysregulation,
they show a general disruption to the expression of genes
that relate to DNA methylation, particular upregulation of
UHRF1, TET1, and TET2. Furthermore, an association between
a decrease in the content of 5-hydroxymethylcytosine and a poor
survival rate highlights the pivotal role of epigenetics.
It seems that there is very much a call for more
targeted therapies regarding the treatment of very many
cancers. Epigenetic changes and reprogramming of the
epigenome are both marks/events that we can readily
reverse. For example and as above in the case of T-ALL,
erasure of the epigenetic marks abrogated NOTCH1-
driven abnormal gene expression. From this and the other
scientific and clinical findings presented in this special issue,
it seems that epigenomics has a bright future regarding
developing a better understanding of cancer and controlling
this disease.
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